



Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017

January 18, 2017

MENLO PARK, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced today its participation in the Phacilitate Cell & Gene Therapy World 2017 conference held January 17-20, 2017 in Miami, Florida. The Company will participate in the following two sessions during the conference:

Session: Vector Manufacturing: Meeting Escalating Demand for In Vivo and Ex Vivo Gene Therapy Applications

Topic: What are your options to alleviate the inefficiency of current AAV, retroviral and lentiviral vector manufacturing systems and minimize impact on cost of goods?

Panel Presenter: Mehdi Gasmi, Ph.D., Chief Technology Officer and Interim Chief Scientific Officer, Adverum Biotechnologies

Date/Time: Thursday, January 19, 2017, 2:30-3:45 p.m. ET

Session: Therapeutic Area R&D Update: CNS & Ophthalmology

Presenter: Mehdi Gasmi, Ph.D., Chief Technology Officer and Interim Chief Scientific Officer, Adverum Biotechnologies

Date/Time: Friday, January 20, 2017, 12:55 – 1:20 p.m. ET

About Adverum Biotechnologies, Inc.

Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverum.com.

Contacts for Adverum:

Leone Patterson

Chief Financial Officer

Adverum Biotechnologies, Inc.

650-665-7222

lpatterson@adverum.com

Jill Steier

Senior Vice President

The Trout Group LLC

646-378-2946

jsteier@troutgroup.com

 [Primary Logo](#)

Adverum Biotechnologies, Inc.